RU2015150233A - Способы лечения злокачественной опухоли - Google Patents
Способы лечения злокачественной опухоли Download PDFInfo
- Publication number
- RU2015150233A RU2015150233A RU2015150233A RU2015150233A RU2015150233A RU 2015150233 A RU2015150233 A RU 2015150233A RU 2015150233 A RU2015150233 A RU 2015150233A RU 2015150233 A RU2015150233 A RU 2015150233A RU 2015150233 A RU2015150233 A RU 2015150233A
- Authority
- RU
- Russia
- Prior art keywords
- fgfr1
- overexpression
- ecd
- individual
- malignant tumor
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 55
- 201000011510 cancer Diseases 0.000 title claims 17
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 36
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 36
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 36
- 230000002018 overexpression Effects 0.000 claims 23
- 230000004927 fusion Effects 0.000 claims 16
- 101150016624 fgfr1 gene Proteins 0.000 claims 15
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 14
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 11
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 11
- 230000003321 amplification Effects 0.000 claims 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims 10
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 7
- 229930012538 Paclitaxel Natural products 0.000 claims 7
- 190000008236 carboplatin Chemical compound 0.000 claims 7
- 229960004562 carboplatin Drugs 0.000 claims 7
- 229960003668 docetaxel Drugs 0.000 claims 7
- 102000015694 estrogen receptors Human genes 0.000 claims 7
- 108010038795 estrogen receptors Proteins 0.000 claims 7
- 229960001592 paclitaxel Drugs 0.000 claims 7
- 239000000186 progesterone Substances 0.000 claims 7
- 229960003387 progesterone Drugs 0.000 claims 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 7
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 claims 4
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 4
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 210000002230 centromere Anatomy 0.000 claims 3
- 210000000349 chromosome Anatomy 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 2
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims 2
- 102100039578 ETS translocation variant 4 Human genes 0.000 claims 2
- 102100035323 Fibroblast growth factor 18 Human genes 0.000 claims 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 2
- 101000951342 Homo sapiens Dickkopf-related protein 3 Proteins 0.000 claims 2
- 101000813747 Homo sapiens ETS translocation variant 4 Proteins 0.000 claims 2
- 101000878128 Homo sapiens Fibroblast growth factor 18 Proteins 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 208000002458 carcinoid tumor Diseases 0.000 claims 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 2
- 239000002474 gonadorelin antagonist Substances 0.000 claims 2
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 claims 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 2
- 238000009396 hybridization Methods 0.000 claims 2
- 108020004999 messenger RNA Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 1
- 102100032187 Androgen receptor Human genes 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- 229940122439 Hydroxylase inhibitor Drugs 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 108010016076 Octreotide Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 238000002105 Southern blotting Methods 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000052 comparative effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 238000002493 microarray Methods 0.000 claims 1
- 229960002700 octreotide Drugs 0.000 claims 1
- 238000003753 real-time PCR Methods 0.000 claims 1
- 238000003757 reverse transcription PCR Methods 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 230000003595 spectral effect Effects 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818220P | 2013-05-01 | 2013-05-01 | |
| US61/818,220 | 2013-05-01 | ||
| US201361831029P | 2013-06-04 | 2013-06-04 | |
| US61/831,029 | 2013-06-04 | ||
| PCT/US2014/036140 WO2014179448A2 (en) | 2013-05-01 | 2014-04-30 | Methods of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015150233A true RU2015150233A (ru) | 2017-06-02 |
Family
ID=50928263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015150233A RU2015150233A (ru) | 2013-05-01 | 2014-04-30 | Способы лечения злокачественной опухоли |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160067307A1 (https=) |
| EP (1) | EP2991669A2 (https=) |
| JP (1) | JP2016526016A (https=) |
| KR (1) | KR20160003141A (https=) |
| CN (1) | CN105188732A (https=) |
| AU (1) | AU2014259956A1 (https=) |
| BR (1) | BR112015027607A8 (https=) |
| CA (1) | CA2908391A1 (https=) |
| HK (1) | HK1213817A1 (https=) |
| MX (1) | MX2015015115A (https=) |
| RU (1) | RU2015150233A (https=) |
| SG (1) | SG11201508878WA (https=) |
| WO (1) | WO2014179448A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1910542B1 (en) | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| JP2015505818A (ja) | 2011-11-14 | 2015-02-26 | ファイブ プライム セラピューティックス インコーポレイテッド | 癌を治療する方法 |
| PH12021552742A1 (en) | 2013-08-01 | 2022-05-23 | Five Prime Therapeutics Inc | Afucosylated anti-fgfr2iiib antibodies |
| BR112018001438A2 (en) * | 2015-07-24 | 2018-12-04 | Debiopharm International S.A. | gffr expression and susceptibility to a gffr inhibitor |
| US20170145103A1 (en) * | 2015-11-23 | 2017-05-25 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
| PL238516B1 (pl) | 2016-06-13 | 2021-08-30 | Univ Wroclawski | Sposób otrzymywania modyfikowanego polipeptydu |
| SG11201906249PA (en) * | 2017-02-06 | 2019-08-27 | Rainier Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| WO2018195273A1 (en) * | 2017-04-19 | 2018-10-25 | The Corporation Of Mercer University | Sam-1 protein, composition and methods of use |
| SG10202112636SA (en) | 2017-05-16 | 2021-12-30 | Five Prime Therapeutics Inc | Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| DK0575545T3 (da) | 1991-03-15 | 2003-09-15 | Amgen Inc | Pegylering af polypeptider |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
| WO2001075166A2 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| KR20130056201A (ko) | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
| US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| JP4810427B2 (ja) | 2003-05-22 | 2011-11-09 | アボット・ラボラトリーズ | インダゾール、ベンズイソオキサゾールおよびベンズイソチアゾールキナーゼ阻害剤 |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| EP1910542B1 (en) * | 2005-07-22 | 2009-12-02 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| CA2626679C (en) * | 2005-11-04 | 2011-08-16 | Merck & Co., Inc. | Methods of treating cancers with saha, carboplatin, and paclitaxel and other combination therapies |
| ES2342646B1 (es) | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| US8481038B2 (en) * | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| JP5945277B2 (ja) * | 2010-11-15 | 2016-07-05 | ファイブ プライム セラピューティックス インコーポレイテッド | Ｆｇｆｒ１細胞外ドメイン併用療法 |
| US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| JP2015505818A (ja) * | 2011-11-14 | 2015-02-26 | ファイブ プライム セラピューティックス インコーポレイテッド | 癌を治療する方法 |
-
2014
- 2014-04-30 AU AU2014259956A patent/AU2014259956A1/en not_active Abandoned
- 2014-04-30 BR BR112015027607A patent/BR112015027607A8/pt not_active IP Right Cessation
- 2014-04-30 SG SG11201508878WA patent/SG11201508878WA/en unknown
- 2014-04-30 WO PCT/US2014/036140 patent/WO2014179448A2/en not_active Ceased
- 2014-04-30 CN CN201480024106.3A patent/CN105188732A/zh active Pending
- 2014-04-30 KR KR1020157033756A patent/KR20160003141A/ko not_active Withdrawn
- 2014-04-30 MX MX2015015115A patent/MX2015015115A/es unknown
- 2014-04-30 HK HK16101949.2A patent/HK1213817A1/zh unknown
- 2014-04-30 RU RU2015150233A patent/RU2015150233A/ru not_active Application Discontinuation
- 2014-04-30 EP EP14729530.7A patent/EP2991669A2/en not_active Withdrawn
- 2014-04-30 JP JP2016512011A patent/JP2016526016A/ja active Pending
- 2014-04-30 CA CA2908391A patent/CA2908391A1/en not_active Abandoned
- 2014-04-30 US US14/785,691 patent/US20160067307A1/en not_active Abandoned
-
2018
- 2018-01-03 US US15/861,047 patent/US20180280470A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201508878WA (en) | 2015-11-27 |
| WO2014179448A3 (en) | 2014-12-24 |
| KR20160003141A (ko) | 2016-01-08 |
| AU2014259956A1 (en) | 2015-11-12 |
| WO2014179448A2 (en) | 2014-11-06 |
| US20160067307A1 (en) | 2016-03-10 |
| EP2991669A2 (en) | 2016-03-09 |
| JP2016526016A (ja) | 2016-09-01 |
| US20180280470A1 (en) | 2018-10-04 |
| BR112015027607A8 (pt) | 2018-01-23 |
| BR112015027607A2 (pt) | 2017-12-05 |
| CN105188732A (zh) | 2015-12-23 |
| CA2908391A1 (en) | 2014-11-06 |
| HK1213817A1 (zh) | 2016-07-15 |
| MX2015015115A (es) | 2016-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015150233A (ru) | Способы лечения злокачественной опухоли | |
| Cyran et al. | Heat shock proteins and HSF1 in cancer | |
| Khan et al. | Recent strategies to overcome breast cancer resistance | |
| Wadosky et al. | Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer | |
| Wang et al. | Aberrant regulation of FBW7 in cancer | |
| Yang et al. | Targeting insulin and insulin-like growth factor signaling in breast cancer | |
| Bibault et al. | Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review | |
| Arienti et al. | Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer | |
| Wang et al. | MiR-183 modulates multi-drug resistance in hepatocellular cancer (HCC) cells via miR-183-IDH2/SOCS6-HIF-1α feedback loop. | |
| Boone et al. | Targeting the insulin-like growth factor receptor: developing biomarkers from gene expression profiling | |
| Ding et al. | Analysis the prognostic values of solute carrier (SLC) family 39 genes in gastric cancer | |
| IL292193B2 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP2015505818A5 (https=) | ||
| JP2016518371A (ja) | Ｈｅｄｇｅｈｏｇ経路阻害剤を用いた増殖障害の処置および予後モニタリングの方法 | |
| CN107427501B (zh) | 通过联合使用治疗癌症的方法 | |
| Xu et al. | Hsa_circ_0001869 promotes NSCLC progression via sponging miR-638 and enhancing FOSL2 expression | |
| JP2014508782A5 (https=) | ||
| Cai et al. | Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation | |
| Zou et al. | RBM38 in cancer: role and mechanism | |
| JP2016526016A5 (https=) | ||
| Flach et al. | The first decade of estrogen receptor cistromics in breast cancer | |
| Chien | A review of the endocrine resistance in hormone-positive breast cancer | |
| Chen et al. | Drug resistance of enzalutamide in CRPC | |
| Kamath et al. | Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery | |
| Zeng et al. | FEN1 knockdown improves trastuzumab sensitivity in human epidermal growth factor 2-positive breast cancer cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20181212 |